Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.42 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | EYA2 | O00167 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669691 | 1.00 | TSHR (0.42) | TSHRTDP1BLMLMNAGABRR1 | |
| SCHEMBL7638775 | 1.00 | TSHR (0.42) | TSHRTDP1BLMLMNAGABRR1 | |
| Hydrochloric Acid SCHEMBL668189 | 0.98 | TSHR (0.41) | TSHRTDP1BLMLMNAGABRR1 | |
| Hydrochloric Acid SCHEMBL668188 | 0.98 | TSHR (0.41) | TSHRTDP1BLMLMNAGABRR1 | |
| SCHEMBL16860061 | 0.82 | ALDH1A1 (0.34) | ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3263081 | 0.82 | ALDH1A1 (0.36) | TSHRTDP1BLMLMNAGABRR1 | |
| SCHEMBL16860063 | 0.82 | ALDH1A1 (0.34) | ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3263078 | 0.82 | ALDH1A1 (0.36) | TSHRTDP1BLMLMNAGABRR1 | |
| Bicarbonate SCHEMBL1081463 | 0.82 | LMNA (0.44) | TSHRTDP1BLMLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL16860066 | 0.80 | ALDH1A1 (0.33) | ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | claimed |
| EP-1950201-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2008-07-30 | — | — | EP | claimed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| EP-3089961-B1 | PROCESS FOR THE MANUFACTURE OF (E)-4-N,N-DIALKYLAMINO CROTONIC ACID IN HX SALT FORM AND USE THEREOF FOR SYNTHESIS OF EGFR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-07-11 | — | — | EP | disclosed |
| EP-3089961-A1 | PROCESS FOR THE MANUFACTURE OF (E)-4-N,N-DIALKYLAMINO CROTONIC ACID IN HX SALT FORM AND USE THEREOF FOR SYNTHESIS OF EGFR TYROSINE KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-11-09 | — | — | EP | disclosed |
| EP-3089961-A1 | PROCESS FOR THE MANUFACTURE OF (E)-4-N,N-DIALKYLAMINO CROTONIC ACID IN HX SALT FORM AND USE THEREOF FOR SYNTHESIS OF EGFR TYROSINE KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9242965-B2 | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9242965-B2 | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9242965-B2 | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2896612-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2015101554-A1 | PROCESS FOR THE MANUFACTURE OF (E)-4-N,N-DIALKYLAMINO CROTONIC ACID IN HX SALT FORM AND USE THEREOF FOR SYNTHESIS OF EGFR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL TRADING (SHANGHAI) CO., LTD: (CN) | 2015-07-09 | — | — | WO | disclosed |
| US-20150183764-A1 | PROCESS FOR THE MANUFACTURE OF (E)-4-N,N-DIALKYLAMINO CROTONIC ACID IN HX SALT FORM AND USE THEREOF FOR SYNTHESIS OF EGFR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-8779192-B2 | Process of preparing an alkylamine derivative | KOLON LIFE SCIENCE, INC. | 2014-07-15 | — | — | US | disclosed |
| EP-2253620-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH HOLDINGS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20120046494-A1 | METHOD OF PREPARING AN ALKYLAMINE DERIVATIVE | KOLON LIFE SCIENCE, INC. (KR) | 2012-02-23 | — | — | US | disclosed |
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1950201-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046494-A1 | METHOD OF PREPARING AN ALKYLAMINE DERIVATIVE | INMT, PNMT, ALKBH2 | TSHR 1506/4885TDP1 1797/4885BLM 413/4885 |
| US-20150183764-A1 | PROCESS FOR THE MANUFACTURE OF (E)-4-N,N-DIALKYLAMINO CROTONIC ACID IN HX SALT FORM AND USE THEREOF FOR SYNTHESIS OF EGFR TYROSINE KINASE INHIBITORS | EGFR, ABL1, CSNK1A1 | TSHR 525/4885TDP1 3004/4885BLM 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.